CN112823667A - Application of composition in preventing or relieving infantile intestinal colic - Google Patents

Application of composition in preventing or relieving infantile intestinal colic Download PDF

Info

Publication number
CN112823667A
CN112823667A CN202010135666.3A CN202010135666A CN112823667A CN 112823667 A CN112823667 A CN 112823667A CN 202010135666 A CN202010135666 A CN 202010135666A CN 112823667 A CN112823667 A CN 112823667A
Authority
CN
China
Prior art keywords
bifidobacterium
composition
infantile
acid glyceride
palmitic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010135666.3A
Other languages
Chinese (zh)
Other versions
CN112823667B (en
Inventor
刘彪
石羽杰
叶文慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Yili Industrial Group Co Ltd
Original Assignee
Inner Mongolia Yili Industrial Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inner Mongolia Yili Industrial Group Co Ltd filed Critical Inner Mongolia Yili Industrial Group Co Ltd
Priority to CN202310545216.5A priority Critical patent/CN116584653A/en
Publication of CN112823667A publication Critical patent/CN112823667A/en
Application granted granted Critical
Publication of CN112823667B publication Critical patent/CN112823667B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pediatric Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention belongs to the field of food or medicine, and particularly discloses application of a composition in preparing food for preventing, reducing or relieving infantile intestinal colic, medicine for preventing or treating infantile intestinal colic or food or medicine for improving infantile excessive internal heat symptoms and/or infantile excessive internal heat behavior expression; wherein the composition comprises glyceryl palmitate, a-lactalbumin, beta-casein and at least one bifidobacterium selected from bifidobacterium lactis, bifidobacterium animalis, bifidobacterium longum, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum and bifidobacterium infantis; wherein the palmitic acid glyceride contains 15% or more of Sn-2 palmitic acid glyceride by weight.

Description

Application of composition in preventing or relieving infantile intestinal colic
Technical Field
The invention belongs to the field of food or medicine, and particularly relates to application of a composition in preventing or relieving infantile intestinal colic.
Background
According to statistics, crying accounts for 20% of the consultation of pediatric inquiry of newborns, wherein a large proportion of infants can have abdominal discomfort symptoms such as colic within 3 months after birth, and the incidence rate of the colic is similar among infants of different sexes and different feeding modes. Intestinal colic is usually benign and gradually disappears from 4 months with the infant growing up. Although infant colic and its resulting nocturnal crying are self-limiting and benign causes, it often leads to fatigue and even depression in parents and caregivers. Therefore, there is a need to find a method or product effective in preventing or alleviating intestinal colic in infants and young children.
Early in life, both the gut and the brain undergo rapid changes, which are also critical periods of colonization and formation of gut microbes. It has been found that a range of factors influence the composition of the gut microbiota early in life, including birth age, mode of production, mode of feeding, genetic background, geographical environment, lactating mothers diet and antibiotic use. Term production, natural normal birth and adherence to pure breast feeding 6 months after birth are favorable factors for the establishment and maturation of the intestinal microbiota in early stage, and can reduce the risks of some acute and chronic diseases, such as obesity, type 1 diabetes, allergy, inflammatory bowel disease and the like. Several studies have now pointed out that infants with colic have a different intestinal flora than normal infants.
The breast milk fat provides 45-60% of energy for the early growth of infants, and more than 98% of the breast milk fat is triglyceride. The positions of different fatty acids in the breast milk esterified with glycerol are different; wherein unsaturated fatty acids such as linoleic acid and alpha-linolenic acid in the breast milk are more than 1 site and 3 sites of the triglyceride; long chain saturated fatty acids such as palmitic acid in breast milk are mainly located at the 2-position, and thus formed palmitic acid triglyceride is called Sn-2 palmitic acid triglyceride. In the digestive tract, the lipolytic enzymes of the infant's stomach act primarily on the 1-and 3-ester bonds of triglycerides, so that unsaturated fatty acids are first freed and then degraded and absorbed in the duodenum along with Sn-2 palmitic acid monoglyceride. However, the common infant formula powder contains palm oil, most of long-chain saturated fatty acids of the palm oil are esterified on ester bonds at the 1-position and the 3-position of triglyceride, and the palm oil is easy to combine with calcium ions after hydrolysis to form calcium soap, so that the absorption of fat and mineral substances is reduced, and the calcium soap which is difficult to absorb can also cause hard excrement to cause difficult defecation. The national standard GB14880 allows OPO structural ester to be added into infant formula powder, which is a food raw material rich in Sn-2 palmitic acid triglyceride, and the content of Sn-2 palmitic acid triglyceride in the product can be increased by adding the OPO structural ester.
Breast milk is rich in a-lactalbumin, a protein rich in essential amino acids, which is digested to produce a variety of biologically active polypeptides. Researches show that the a-lactalbumin digestion product can inhibit pathogenic bacteria such as escherichia coli, pneumococcus, staphylococcus aureus, candida and the like in vitro.
Beta-casein is a casein molecule with the highest content in breast milk, and a polypeptide fragment generated by digestion has the effect of inhibiting the growth of harmful bacteria.
Probiotics are an important component of the gut microbiota. The definitions of probiotics by the world Food and Agriculture Organization (FAO) and the World Health Organization (WHO) are: by ingesting a suitable amount of live bacteria, the live bacteria can exert an effective effect on the health of the consumer. The bifidobacterium is one of probiotics, and the currently common bifidobacterium strains comprise bifidobacterium lactis, bifidobacterium animalis, bifidobacterium longum, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum, bifidobacterium infantis and the like, and a plurality of novel strains.
Disclosure of Invention
The invention provides application of the composition in preventing or relieving infantile intestinal colic, or improving infantile excessive internal heat symptoms and/or excessive internal heat behavior.
The invention relates to application of a composition in preparing food for preventing, reducing or relieving infantile intestinal colic, medicine for preventing or treating infantile intestinal colic or food or medicine for improving infantile excessive internal heat symptoms and/or infantile excessive internal heat behavior; wherein the composition comprises glyceryl palmitate, a-lactalbumin, beta-casein and at least one bifidobacterium selected from bifidobacterium lactis, bifidobacterium animalis, bifidobacterium longum, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum and bifidobacterium infantis; wherein the palmitic acid glyceride contains 15% or more (for example, 18% or more, 20% or more, 15% to 98%, 15% to 90%, 20% to 80%, 20% to 95%, 30%, 40%, 50%, 60%, 70%) by weight of Sn-2 palmitic acid glyceride.
In some embodiments of the invention, the glyceryl palmitate comprises Sn-2 glyceryl palmitate and optionally any other glyceryl palmitate other than Sn-2 glyceryl palmitate.
In some embodiments of the invention, the weight ratio between the a-lactalbumin, the beta-casein and the Sn-2 glyceryl palmitate is (1-10): (1-10): 1-10), such as 1 (1-2): 1-2), 1 (1-5): 1-5), 1 (1-7): 1-7), 1 (1-6): 1-6), 1:1.32:1.2, 1:1:1, 1:3:3, 1:5:5, 1:8: 8.
In some embodiments of the invention, the viable count of bifidobacteria10 per gram of a-lactalbumin7～1013CFU, e.g. 108CFU、109CFU、1010CFU、1011CFU、1012CFU。
In some embodiments of the invention, the bifidobacterium is selected from bifidobacterium BB12 and bifidobacterium HN 019.
In some embodiments of the invention, the ratio of viable count of bifidobacterium BB12 to bifidobacterium HN019 is (1:100) to (100:1), for example 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 40:1, 30:1, 20:1, 10:1, 5:1, 1:5, 1:8, 1:10, 1:14, 1:17, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1: 90.
In some embodiments of the invention, the composition further comprises a fat other than glyceryl palmitate.
In some embodiments of the invention, fats other than palmitic acid glycerides are fats commonly used in the art.
In some embodiments of the invention, the fat other than palmitic acid glyceride is selected from the group consisting of linoleic acid glyceride, linolenic acid glyceride, docosahexaenoic acid glyceride, and arachidonic acid glyceride.
In some embodiments of the invention, the weight of the palmitic acid glyceride in the composition is 1% to 96% of the total weight of the fat, calculated as fatty acid, for example 10% to 90%, 20% to 80%, 30% to 70%, 20% to 90%, 10% to 50%, 5% to 40%, 5% to 60%. Wherein the fat is formed by combining fatty acid and glycerol.
In some embodiments of the invention, the composition further comprises a protein other than a-whey protein and beta-casein.
In some embodiments of the invention, the proteins other than a-lactalbumin and β -casein are proteins commonly used in the art.
In some embodiments of the invention, the protein other than a-lactalbumin and β -casein is selected from ovalbumin, egg phosphoprotein, albumin, myoprotein, soy protein, glutenin, gluten, gliadin, zein, collagen, legumin and milk proteins other than a-lactalbumin and β -casein.
In some embodiments of the invention, the composition further comprises a carbohydrate.
In some embodiments of the invention, the carbohydrate is a carbohydrate commonly used in the art.
In some embodiments of the invention, the carbohydrate is selected from the group consisting of glucose, fructose, galactose, sucrose, lactose, maltose, starch, cellulose, hemicellulose, and pectin.
In some embodiments of the present invention, the composition further comprises a pharmaceutical excipient and optionally a pharmaceutical active ingredient for preventing or alleviating infantile colic, or improving infantile symptoms of excessive internal heat and/or infantile manifestations of excessive internal heat, or the composition further comprises a food additive.
In some embodiments of the present invention, the pharmaceutical excipient is a pharmaceutical excipient commonly used in the art.
In some embodiments of the invention, the pharmaceutical excipients may be selected from solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, tonicity adjusting agents, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integration agents, penetration enhancers, pH adjusting agents, buffers, plasticizers, surfactants, foaming agents, antifoaming agents, thickeners, encapsulation agents, humectants, absorbents, flocculants and deflocculants, filter aids, and release retardants.
In some embodiments of the invention, the food additive may be selected from the group consisting of dietary supplements, antioxidants, taste enhancers, sweeteners, thickeners, preservatives, anti-caking agents, and acidity regulators.
In some embodiments of the invention, the nutritional supplement may be selected from vitamins (e.g., vitamin A, B)1、B6、B12C, D, E), minerals (e.g., magnesium, phosphorus, calcium, iron, zinc, selenium or their derivatives, etc.), dietary fiber, taurine, and choline.
In some embodiments of the invention, the food product is a dairy product.
In some embodiments of the invention, the dairy product contains 0.5-16 g a-whey protein per hundred grams, such as 1g, 2g, 3g, 4g, 5g, 6g, 7g, 8g, 9g, 10g, 11g, 12g, 13g, 14g, 15 g.
In some embodiments of the invention, the dairy product contains 0.8-20 g of beta-casein per hundred grams, such as 1g, 2g, 3g, 4g, 5g, 6g, 7g, 8g, 9g, 10g, 11g, 12g, 13g, 14g, 15g, 16g, 17g, 18g, 19 g.
In some embodiments of the invention, the viable count of bifidobacteria per hundred grams of dairy product is 106～1015CFU, e.g. 107CFU、108CFU、109CFU、1010CFU、1011CFU、1012CFU、1013CFU、1014CFU。
In some embodiments of the invention, the symptoms of an infant's excessive internal heat are selected from the group consisting of redness of the face, redness and swelling of the eyes, scanty eyes, dry lips, bad breath, runny or yellow nasal discharge, fever in the palms and soles, yellow urine, thickened tongue coating, and hard stools.
In some embodiments of the invention, the infant's performance of getting on fire is selected from waking up and crying at night, splenic irritability, angry, crying during the day, being hungry more than usual, eating less than usual, kicking away quilt, and not wearing clothes.
In the invention, the dairy product is selected from at least one of sterilized milk, reconstituted milk, yoghourt, yogurt, milk powder, formula milk powder, condensed milk, cheese, casein, whey powder, milk fat and milk-containing beverage, and is preferably (infant) formula milk powder.
In the present invention, unless otherwise specified, wherein:
the term "glyceryl palmitate" refers to fatty acid glycerides having at least one palmitic acid attached to a glyceryl moiety, and may be selected from monoesters, diesters and triesters, wherein other fatty acid moieties may also be attached to the glyceryl moieties of the diesters, triesters.
The term "Sn-2 palmitic acid" refers to palmitic acid attached to the Sn-2 position on a glyceryl portion of a fat.
The term "Sn-2 glyceryl palmitate" refers to fatty acid glycerides with palmitic acid attached to the Sn-2 position of the glyceryl moiety, and may be selected from the group consisting of Sn-2 monoglycerides, Sn-2 diglycerides and Sn-2 triglycerides; wherein, any fatty acid can be connected to the Sn-1 position and/or the Sn-3 position on the glyceryl in the Sn-2 palmitic acid diglyceride and the Sn-2 palmitic acid triglyceride, and the fatty acid comprises, but is not limited to, palmitic acid, butyric acid, caproic acid, caprylic acid, capric acid, stearic acid, lauric acid, myristic acid, arachic acid, myristoleic acid, palmitoleic acid, rapeseed oleic acid, linoleic acid, linolenic acid and the like.
The term "a-lactalbumin" is a protein extracted from milk, has the characteristics of high nutritional value, easy digestion and absorption, various active ingredients and the like, and is one of high-quality protein supplements for human bodies.
The term "beta-casein" is a phosphorylated protein synthesized by mammary acinar epithelial cells and is widely found in the milk of mammals (cows, yaks, goats, horses, rabbits, etc.) and humans.
The invention has the following beneficial effects:
the invention provides application of the composition in preventing, reducing or relieving infantile intestinal colic, or improving infantile inflammation symptoms and/or infantile inflammation behavior.
Drawings
In order that the present disclosure may be more readily and clearly understood, reference is now made to the following detailed description of the embodiments of the present disclosure taken in conjunction with the accompanying drawings, in which
FIG. 1 is a graph showing the incidence of colic in infants in the test, control and breast milk groups at different time points;
FIG. 2 is a graph of the mean score of the difference between the overall score of fire symptoms and performance at each time point and the baseline overall score of fire symptoms and performance for infants in the test, control and breast milk groups;
FIG. 3 is a graph of the average score of the difference between the fire performance score at each time point and the baseline fire performance score for infants in the test, control and breastmilk groups;
FIG. 4 is a graph showing the average score of differences between the night wake cry scores of infants in the test, control and breast milk groups at various time points and the baseline night wake cry scores.
Detailed Description
Embodiments of the present invention will now be described more fully hereinafter with reference to the accompanying examples, in which some, but not all embodiments of the invention are shown. The following description of at least one exemplary embodiment is merely illustrative in nature and is in no way intended to limit the invention, its application, or uses. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Examples
Formula milk powder was prepared according to the example formula in table 1. Each hundred grams of milk powder contains about 2.17g of Sn-2 palmitic acid glyceride.
TABLE 1
Figure BDA0002397220680000071
Figure BDA0002397220680000081
Comparative example
Formula milk powder was prepared according to the control formula in table 1. Each hundred grams of milk powder contains about 0.7g of Sn-2 palmitic acid glyceride.
Clinical test method and test results
Randomized control design, the feeding effect of the example formula was compared to the control formula.
1. Grouping of subjects:
infants in need of inclusion were screened by recruiting screening questionnaires by pediatricians or trained researchers. Written informed consent was obtained from the mother prior to study entry.
1.1 inclusion criteria
And (3) full-term infants: the gestational week is more than or equal to 37 weeks;
birth weight: 2.5kg-4 kg;
normal pregnancy, delivered baby (including cesarean);
healthy, Apgar score > 7 after birth for 5-10 minutes;
age: < 15 days.
1.2 exclusion criteria
Infants with any of the following characteristics were excluded:
congenital malformations or chromosomal disorders detected at birth and of clinical significance;
patients with disease requiring mechanical ventilation or medication within one week after birth (infant jaundice patients who do not include blue light therapy);
those who affect feeding or metabolism due to suspected or unknown metabolic factors or due to physical defects;
twins or multiple births.
1.3 Experimental groups
Selecting full-term infants of 0-6 months as study objects, wherein the breast milk of the infants is sufficient after birth, and mothers are willing to basically feed the full-term infants to the full-term infants of 6 months as a breast milk group; the breast feeding can not be carried out, the infant formula milk powder is determined to be used for feeding, the feeding amount of the infant formula milk powder at the age of 1-15 days is more than or equal to 250ml/d, the dry prognosis milk powder is started to feed more than 80 percent of infants, and the infants are randomly divided into a test group (feeding the formula milk powder of the example) and a control group (feeding the control formula milk powder). The number of people in each group is not less than 5.
2. Intervention study method
Baseline (postnatal day 15) surveys and sample collections were performed on the enrolled infants, followed by continuous feeding for 6 months. During this period, the study investigators followed subjects 4 weeks, 6 weeks, 8 weeks, 16 weeks, and 24 weeks after initiation of feeding. The basic population sociology, colic occurrence and excessive internal heat of the infant were investigated.
3. Results of clinical experiments
3.1 basic demographic sociological conditions of infants in different experimental groups
The findings of the infants in the three experimental groups were compared: the social and demographic distributions of the test group, the breast-milk group and the control group are similar, except that the father working condition, the highest parental school calendar and the family income of the infants of the test group and the breast-milk group are slightly different, but the existing documents and reports for comparing and researching the breast-feeding and the formula-feeding of the infants generally show the differences, so the differences do not hinder or influence the comparison of the research results of the experiment. In addition, as shown in table 3.1: the gender ratio of the three groups of infants was not significantly different; the vaginal delivery rate of the breast milk group was higher than that of the test group and the control group, and there was no difference between the vaginal delivery rates of the test group and the control group; the T-test p-values for the breast milk group or control and test group data are also provided in table 3.1, with p-values < 0.05 indicating statistical differences and p-values < 0.01 indicating significant statistical differences.
TABLE 3.1 infant gender and delivery modality constitution
Figure BDA0002397220680000091
Figure BDA0002397220680000101
3.2 incidence of colic in infants from different experimental groups
The incidence (%) of colic was observed in the infants of the three experimental groups and the results are shown in FIG. 1.
As can be seen from fig. 1, although the incidence of colic was higher in the infants in the test group than in the control group at baseline, the incidence of colic was significantly lower in the infants in the test group after week 6 as the feeding time was extended; moreover, the highest incidence of colic in the infants of the test group appeared at weeks 6-8 and then gradually declined, approaching the trend of the breast milk group, while the highest incidence of colic in the infants of the control group appeared at week 16, which was not reduced all the time, and brought more stress to the infants and family. This shows that the formula milk powder of the invention can effectively relieve or improve the symptoms of intestinal colic of infants.
3.3 flaming of infants in different groups
According to the theory of traditional Chinese medicine, the infants generally have the symptoms of red complexion, red and swollen eyes, much excrement, dry lips, halitosis (peculiar smell except milk smell), snivel slag or yellow snivel, fever of hands and feet, yellow urine, thickened tongue fur and hard stool after getting inflamed, and also show the behaviors of waking up and crying at night, splenic qi impatience, loving vitality, crying in daytime, being hungry more than usual, eating less than usual, kicking quilt and not wearing clothes. The infants in the three experimental groups were observed and scored for the onset of the above-mentioned symptoms of excessive internal heat and performance at baseline (day 15 after birth), at weeks 4, 6, 16, and 24. Grading standard: except for the defecation condition, one symptom or behavior is divided into one point when the symptom or behavior appears, and the other point is not divided when the symptom or behavior does not appear; if the excrement is water-like, adding one minute; if the stool is soft, adding dichotomy; adding radix Anisodi Acutanguli if the stool is slightly shaped; if the stool is dry and hard, adding four parts; if the stool is very dry and hard, five cents are added. The average score of the difference between the overall score for fire symptoms and performance at each time point and the overall score for fire symptoms and performance at baseline for each group of infants is shown in figure 2. The average score of the difference between the fire performance score at each time point and the baseline fire performance score for each group of infants is shown in figure 3. The average score of the difference between the score for each group of infants waking up and crying at each time point night and the score for waking up and crying at baseline night is shown in fig. 4.
As can be seen from FIG. 2, the improvement of the degree of inflammation of the infants in the test group and the control group relative to the baseline at week 4 was similar, and then the degree of inflammation of the infants in the test group was gradually relieved as the feeding time was prolonged, and the degree of inflammation was significantly lower at week 24 than at week 4; while the degree of the fire in the infants in the control group was greatly increased at weeks 4-6, then returned to the level at week 4 at week 8, and then further increased at weeks 8-16 until week 24 was only slightly relieved from week 4, but was still much more severe than the degree of the fire at week 24 in the infants in the test group. As can be seen from FIG. 3, the infants in the test group had better improvement in the performance of the fire at week 4 relative to baseline than the infants in the control group; thereafter, the control group had an increased degree of the onset of fire behavior, which was not relieved until weeks 16-24, but was still much more severe than the test group; the performance of the infants in the test group was improved gradually from 4 th to 24 th weeks, and the performance of the infants in the breast milk group was similar to the performance of the infants in the breast milk group. As can be seen from FIG. 4, the infants in the control group consistently cried more severely than the infants in the test group. This shows that the formula milk powder of the invention is helpful for improving the symptoms and the performance of the internal heat of infants.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.

Claims (10)

1. The composition is used for preparing food for preventing, reducing or relieving infantile intestinal colic, medicine for preventing or treating infantile intestinal colic or food or medicine for improving infantile excessive internal heat symptoms and/or infantile excessive internal heat behavior; wherein the content of the first and second substances,
the composition comprises palmitic acid glyceride, a-lactalbumin, beta-casein and at least one bifidobacterium selected from bifidobacterium lactis, bifidobacterium animalis, bifidobacterium longum, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum and bifidobacterium infantis; wherein the content of the first and second substances,
the palmitic acid glyceride contains Sn-2 palmitic acid glyceride in an amount of 15 wt% or more based on palmitic acid.
2. The use as in claim 1, wherein the weight ratio between a-lactalbumin, β -casein and Sn-2 glyceryl palmitate in the composition is (1-10): (1-10).
3. Use according to claim 1 or 2, wherein the composition has a viable count of bifidobacteria of 10 per gram of a-lactalbumin7～1013CFU。
4. Use according to any one of claims 1 to 3, wherein in the composition the Bifidobacterium is selected from Bifidobacterium BB12 and Bifidobacterium HN 019;
preferably, the ratio of viable count of bifidobacterium BB12 to bifidobacterium HN019 is (1:100) to (100: 1).
5. Use according to any one of claims 1 to 4, wherein the composition further comprises a fat other than glyceryl palmitate;
preferably, the fat other than palmitic acid glyceride is selected from linoleic acid glyceride, alpha-linolenic acid glyceride, docosahexaenoic acid glyceride and arachidonic acid glyceride;
preferably, the weight of the palmitic acid glycerides in the composition is 1-96% of the total weight of the fat, calculated as fatty acids.
6. Use according to any one of claims 1 to 5, wherein the composition further comprises proteins other than a-whey protein and β -casein;
preferably, the protein other than a-lactalbumin and β -casein is selected from ovalbumin, egg phosphoprotein, albumin, myoprotein, soy protein, glutenin, gluten, gliadin, zein, collagen, legumin and milk proteins other than a-lactalbumin and β -casein.
7. Use according to any one of claims 1 to 6, wherein the composition further comprises a carbohydrate;
preferably, the carbohydrate is selected from the group consisting of glucose, fructose, galactose, sucrose, lactose, maltose, starch, cellulose, hemicellulose and pectin.
8. The use according to any one of claims 1 to 7, wherein the symptoms of infantile excessive internal heat are selected from the group consisting of redness of the face, redness and swelling of the eyes, scanty eye feces, dry lips, halitosis, runny or yellow nasal discharge, fever in the palms and soles, yellow urine, thickened tongue coating and hard stools.
9. Use according to any one of claims 1 to 7, wherein the infant's performance of getting on fire is selected from waking up and crying at night, splenic irritability, loving anger, crying during the day, being hungry more than usual, eating less than usual, kicking off and not wearing clothes.
10. Use according to any one of claims 1 to 9, wherein the food product is a dairy product;
preferably, the viable count of bifidobacteria per hundred grams of dairy product is 106～1015CFU。
CN202010135666.3A 2019-11-20 2020-03-02 Application of composition in preventing or relieving infant colic Active CN112823667B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310545216.5A CN116584653A (en) 2019-11-20 2020-03-02 Application of composition in preventing or relieving infant colic

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911142713 2019-11-20
CN2019111427130 2019-11-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310545216.5A Division CN116584653A (en) 2019-11-20 2020-03-02 Application of composition in preventing or relieving infant colic

Publications (2)

Publication Number Publication Date
CN112823667A true CN112823667A (en) 2021-05-21
CN112823667B CN112823667B (en) 2023-06-02

Family

ID=70862730

Family Applications (8)

Application Number Title Priority Date Filing Date
CN201911345399.6A Pending CN112823646A (en) 2019-11-20 2019-12-24 Composition, food or drug and use thereof
CN202010104301.4A Active CN111227044B (en) 2019-11-20 2020-02-20 Dairy product, preparation method and medical application thereof
CN202010104302.9A Active CN111248287B (en) 2019-11-20 2020-02-20 Application of dairy product in improving neurodevelopment
CN202010104314.1A Active CN111227045B (en) 2019-11-20 2020-02-20 Application of dairy product in promoting growth of length of mammal
CN202010135335.XA Active CN112823647B (en) 2019-11-20 2020-03-02 Application of composition in improving or promoting growth of infant
CN202010135666.3A Active CN112823667B (en) 2019-11-20 2020-03-02 Application of composition in preventing or relieving infant colic
CN202310545216.5A Pending CN116584653A (en) 2019-11-20 2020-03-02 Application of composition in preventing or relieving infant colic
CN202010135640.9A Active CN112823648B (en) 2019-11-20 2020-03-02 Composition, food or medicine and application thereof

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CN201911345399.6A Pending CN112823646A (en) 2019-11-20 2019-12-24 Composition, food or drug and use thereof
CN202010104301.4A Active CN111227044B (en) 2019-11-20 2020-02-20 Dairy product, preparation method and medical application thereof
CN202010104302.9A Active CN111248287B (en) 2019-11-20 2020-02-20 Application of dairy product in improving neurodevelopment
CN202010104314.1A Active CN111227045B (en) 2019-11-20 2020-02-20 Application of dairy product in promoting growth of length of mammal
CN202010135335.XA Active CN112823647B (en) 2019-11-20 2020-03-02 Application of composition in improving or promoting growth of infant

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202310545216.5A Pending CN116584653A (en) 2019-11-20 2020-03-02 Application of composition in preventing or relieving infant colic
CN202010135640.9A Active CN112823648B (en) 2019-11-20 2020-03-02 Composition, food or medicine and application thereof

Country Status (1)

Country Link
CN (8) CN112823646A (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112823646A (en) * 2019-11-20 2021-05-21 内蒙古伊利实业集团股份有限公司 Composition, food or drug and use thereof
CN114223721A (en) * 2020-09-09 2022-03-25 内蒙古伊利实业集团股份有限公司 Application of palmitic acid glyceride in improving or promoting protein absorption of infants
CN114287478A (en) * 2021-11-23 2022-04-08 临夏燎原乳业产业研究院有限公司 Formula yak milk powder for promoting height increase and brain development of children and preparation method thereof
CN114145346A (en) * 2021-11-29 2022-03-08 内蒙古伊利实业集团股份有限公司 Food composition, application of food composition in improving or promoting magnesium absorption and infant formula milk powder
CN114145458A (en) * 2021-11-29 2022-03-08 内蒙古伊利实业集团股份有限公司 Application of palmitic acid glyceride in preparing composition for improving or promoting magnesium absorption of human body
CN115669945B (en) * 2022-10-24 2024-03-08 上海艾斯顿医疗科技有限公司 Liposome-coated polypeptide with neurotrophic effect, and preparation method and application thereof
CN116369527A (en) * 2023-03-09 2023-07-04 江南大学 Bifidobacterium breve capable of regulating bone development and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150237902A1 (en) * 2012-09-11 2015-08-27 Nucitec, S.A. De C.V. Infant formula for optimal growth, gastrointestinal protection and immunological protection of infants
AU2018101868A4 (en) * 2017-12-01 2019-01-17 Noumi Ip Pty Ltd Milk Substitute Compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012335224B2 (en) * 2011-11-10 2016-10-13 Société des Produits Nestlé S.A. Infant formula with high sn-2 palmitate and oligofructose
CN102524421B (en) * 2011-12-31 2013-05-22 黑龙江省完达山乳业股份有限公司 Novel acid-base balance infant formula milk powder and preparation method thereof
MX2012010487A (en) * 2012-09-11 2014-03-26 Nucitec Sa De Cv Composition of nutrients and bioactive substances which promote growth and reduce intolerance and side effects in premature infants.
CN103053694A (en) * 2013-02-18 2013-04-24 杨凌圣妃乳业有限公司 Infant goat milk powder simulating components of breast milk and preparation method thereof
FR3005392B1 (en) * 2013-05-07 2015-09-18 United Pharmaceuticals ANTI-REGURGITATION COMPOSITION PRESERVING INTESTINAL TRANSIT
CN104351356A (en) * 2014-11-25 2015-02-18 澳优乳业（中国）有限公司 Novel fourth-generation infant formula and preparation method thereof
CN105767213A (en) * 2014-12-26 2016-07-20 丰益(上海)生物技术研发中心有限公司 Grease composition and preparation method thereof
CN106259952B (en) * 2015-06-01 2019-01-15 内蒙古伊利实业集团股份有限公司 1-3 years old baby formulas milk powder and preparation method thereof containing nucleotide and dietary fiber
CN106259953B (en) * 2015-06-01 2019-01-29 内蒙古伊利实业集团股份有限公司 Breast milk 0-12 month babies ' formula milk powder containing nucleotide and preparation method thereof
CN105053217A (en) * 2015-09-14 2015-11-18 海普诺凯营养品有限公司 Infant formula ewe milk powder and production method thereof
CN107439686A (en) * 2016-05-31 2017-12-08 内蒙古伊利实业集团股份有限公司 A kind of full-cream chocolate milk and preparation method thereof
CN107668211B (en) * 2017-11-13 2021-08-10 海普诺凯营养品有限公司 Infant formula goat milk powder for enhancing immune function and preparation method thereof
CN110063372A (en) * 2018-01-23 2019-07-30 天津澳斯乳业有限公司 A kind of infant formula goat milk powder and its production method
CN108157512A (en) * 2018-02-05 2018-06-15 高培（广州）乳业有限公司 A kind of formula milk for strengthening 6 ~ 12 months infant's gastrointestinal functions
CN108013143A (en) * 2018-02-05 2018-05-11 高培（广州）乳业有限公司 One kind strengthens the formula milk of 12 ~ 36 months infant's gastrointestinal functions
CN112823646A (en) * 2019-11-20 2021-05-21 内蒙古伊利实业集团股份有限公司 Composition, food or drug and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150237902A1 (en) * 2012-09-11 2015-08-27 Nucitec, S.A. De C.V. Infant formula for optimal growth, gastrointestinal protection and immunological protection of infants
AU2018101868A4 (en) * 2017-12-01 2019-01-17 Noumi Ip Pty Ltd Milk Substitute Compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
刘元法主编: "《食品专用油脂》", 30 June 2017, 中国轻工业出版社 *
史瑞雪等: "益生菌在婴幼儿食品中的应用研究现状", 《现代食品》 *
李宁主编: "《协和营养师告诉你0-3岁宝宝应该这样吃》", 31 August 2013, 中国妇女出版社 *
杨秀珍: "微生态制剂在儿科临床中应用前景", 《中华预防医学会微生态学学会 第四届全国临床儿科微生态学术研讨会论文汇编》 *

Also Published As

Publication number Publication date
CN112823647B (en) 2023-04-07
CN112823667B (en) 2023-06-02
CN112823648A (en) 2021-05-21
CN112823648B (en) 2023-03-31
CN111248287B (en) 2023-04-14
CN112823646A (en) 2021-05-21
CN112823647A (en) 2021-05-21
CN111227044B (en) 2023-05-16
CN111248287A (en) 2020-06-09
CN116584653A (en) 2023-08-15
CN111227045B (en) 2023-04-14
CN111227044A (en) 2020-06-05
CN111227045A (en) 2020-06-05

Similar Documents

Publication Publication Date Title
CN112823667B (en) Application of composition in preventing or relieving infant colic
CN1838888B (en) Baby or second stage formula milk
EP1976397B1 (en) Infant immunological formula
EP2295535A1 (en) Probiotic material
TW201028104A (en) Nutritional composition to promote healthy development and growth
US20130089572A1 (en) Partially Hydrolyzed Casein-Whey Nutritional Compositions For Reducing The Onset Of Allergies
CN106535915B (en) Ghrelin secretion promoter
MX2013005943A (en) Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions.
CN105324033A (en) Fermented nutrition high in lactose with increased iron bioavailability
JP2023503401A (en) A mixture of HMOs to improve the microflora of pregnant women
Singh et al. Goat milk composition and nutritional value: A review
CA3209353A1 (en) Infant formulas containing human breast milk proteins
CN111227046B (en) Application of dairy product in improving infant intestinal SIgA level
HRP20020647A2 (en) A method for maintaining or improving the synthesis of mucins
EP3897608B1 (en) Dietary butyrate for treating or preventing an allergic disorder
JP4307475B2 (en) Infant nutrition composition
US20220000164A1 (en) Nutritional compositions, their use in reducing metabolic stress and method of reducing metabolic stress
WO2021093880A1 (en) Synergistic combination of butyric-acid-producing prebiotics and probiotics
CN114223721A (en) Application of palmitic acid glyceride in improving or promoting protein absorption of infants
CN114145458A (en) Application of palmitic acid glyceride in preparing composition for improving or promoting magnesium absorption of human body
CN114145346A (en) Food composition, application of food composition in improving or promoting magnesium absorption and infant formula milk powder

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant